Astrazeneca Share News (AZN)

Astrazeneca Information

Buy AZN Shares
Add AZN to Watchlist
Add AZN to Alert

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 12,190.00

Bid: 12,210.00

Ask: 12,214.00

Change: 162.00 (1.35%)

Spread: 4.00 (0.033%)

Open: 12,036.00

High: 12,214.00

Low: 12,024.00

Prev. Close: 12,028.00

Last checked at -

BROKER RATINGS SUMMARY: Cantor Upgrades easyJet To Buy From Hold

Tue, 09th Aug 2016 08:33

LONDON (Alliance News) - The following shares received analyst recommendations Tuesday morning and Monday:
----------
FTSE 100
----------
CANTOR FITZGERALD RAISES EASYJET TO 'BUY' ('HOLD') - TARGET 1300 PENCE
----------
TRADERS: MACQUARIE CUTS AVIVA TO 'NEUTRAL' ('OUTPERFORM')
----------
GOLDMAN CUTS AVIVA PRICE TARGET TO 480 (485) PENCE - 'BUY'
----------
BERENBERG RAISES RSA INSURANCE PRICE TARGET TO 501 (448) PENCE - 'HOLD'
----------
CITIGROUP REVISES STANDARD CHARTERED PRICE TARGET TO 750 PENCE - 'BUY'
----------
GOLDMAN RAISES STANDARD CHARTERED PRICE TARGET TO 760 (740) PENCE - 'BUY'
----------
CITIGROUP RAISES HSBC PRICE TARGET TO 600 (515) PENCE - 'BUY'
----------
GOLDMAN RAISES RBS PRICE TARGET TO 240 (235) PENCE - 'BUY'
----------
GOLDMAN CUTS LLOYDS PRICE TARGET TO 53 (55) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES BARCLAYS PRICE TARGET TO 175 (170) PENCE - 'NEUTRAL'
----------
TRADERS: NUMIS CUTS INFORMA TO 'ADD' ('BUY')
----------
RBC RAISES ANTOFAGASTA PRICE TARGET TO 500 (410) PENCE - 'SECTOR PERFORM'
----------
DEUTSCHE BANK RAISES BUNZL PRICE TARGET TO 2520 (2100) PENCE - 'BUY'
----------
JPMORGAN RAISES ASTRAZENECA PRICE TARGET TO 4900 (4800) PENCE - 'NEUTRAL'
----------
CREDIT SUISSE RAISES RELX PRICE TARGET TO 1370 (1210) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
LIBERUM CUTS SERCO GROUP TO 'HOLD' ('BUY') - TARGET 135 (120) PENCE
----------
RBC RAISES INDIVIOR PRICE TARGET TO 325 (185) PENCE - 'SECTOR PERFORM'
----------
GOLDMAN RAISES WILLIAM HILL PRICE TARGET TO 320 (310) PENCE - 'NEUTRAL'
----------
DEUTSCHE BANK CUTS WILLIAM HILL PRICE TARGET TO 390 (420) PENCE - 'BUY'
----------
DEUTSCHE BANK RAISES LADBROKES PRICE TARGET TO 148 (136) PENCE - 'HOLD'
----------
SHORE CAPITAL RAISES OCADO TO 'HOLD' ('SELL')
----------
JPMORGAN CUTS JLT GROUP PRICE TARGET TO 850 (1020) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES MEGGITT PRICE TARGET TO 445 (395) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES JD WETHERSPOON PRICE TARGET TO 980 (840) PENCE - 'BUY'
----------
CREDIT SUISSE RAISES RENTOKIL INITIAL PT TO 235 (225) PENCE - 'OUTPERFORM'
----------
TRADERS: MACQUARIE RAISES PARAGON GROUP TO 'OUTPERFORM' ('NEUTRAL')
----------
GOLDMAN RAISES VEDANTA RESOURCES PRICE TARGET TO 440 (425) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES METRO BANK PRICE TARGET TO 1630 (1560) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES BBA AVIATION PRICE TARGET TO 285 (186) PENCE - 'NEUTRAL'
----------
MAIN MARKET AND AIM
----------
LIBERUM RAISES BOOHOO PRICE TARGET TO 90 (80) PENCE - 'BUY'
----------
TRADERS: NUMIS RAISES SDL TO 'ADD' ('HOLD')
----------
TRADERS: NUMIS RAISES DEVRO TO 'BUY' ('ADD')
----------
BERENBERG CUTS MOTHERCARE PRICE TARGET TO 100 (130) PENCE - 'SELL'
----------
BERENBERG CUTS CARPETRIGHT PRICE TARGET TO 230 (450) PENCE - 'HOLD'
----------
BERENBERG CUTS TOPPS TILES PRICE TARGET TO 125 (155) PENCE - 'HOLD'
----------
PANMURE RAISES GEMFIELDS RESOURCES PRICE TARGET TO 61 (57) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News

23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Latest Share Chat

Astrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Cantor Upgrades easyJet To Buy From Hold

Login to your account

Quickpicks are a member only feature

Login to your account